# OnCo record keynote-590 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-590/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-590", "NCT03189719" ;
  schema:name "KEYNOTE-590"@en ;
  schema:description "Added immunotherapy to first-line chemotherapy for all types of oesophageal cancer, with a survival benefit that held at five years."@en ;
  schema:url <https://onco.cc/trials/keynote-590/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03189719> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2017-07-25" ;
  onco:cancers <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/cps/> ;
  onco:people <https://onco.cc/people/ken-kato/> .